# Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

> **NCT06279767** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 27 (estimated)

## Conditions studied

- Glioblastoma
- Cancer
- Temozolomide

## Interventions

- **DRUG:** 6-mercaptopurine

## Key facts

- **NCT ID:** NCT06279767
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-07-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06279767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06279767, "Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06279767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*